Nipro Medical Corp., a global leader in the healthcare and medical device industry, will spend $397.8 million to build its first North American manufacturing center of excellence in Greenville, North Carolina, an investment that will generate 232 new jobs in Pitt County, according to a press release from the Economic Development Partnership of North Carolina (EDPNC).
“North Carolina’s highly skilled workforce, top-notch education system and leadership in the life sciences industry continue to attract projects to our state that make a difference in the lives of everyday North Carolinians,” said EDPNC CEO Christopher Chung.
“This project will be Nipro’s U.S. headquarters and a new manufacturing facility. (It) will enhance the long-lasting relationship between our state and Japan and build further on our existing life sciences industry,” Chung added.
Nipro Medical Corp. manages the sales, marketing and business operations in North and South America for its parent company in Japan. Since 1954, Nipro Corp. Japan has manufactured products such as needles, infusion sets, catheters and dialyzers for the medical and biopharmaceutical fields.
The company sells products worldwide, operates 27 manufacturing plants and offices in more than 56 countries, and employs more than 29,000 people.
The new 550,000-square-foot campus in Greenville will host a training center for healthcare providers and a customer service center and make high-end medical devices for the North American market.
From 2014 to 2023, Japanese investment in North Carolina amounted to $17.58 billion and created 9,220 jobs, accounting for nearly half of all foreign direct investment in the state and making Japan its largest source of FDI.
Currently, more than 30,500 North Carolinians work for 225 Japanese companies, including HondaJet, FUJIFILM Diosynth Biotechnologies, and Sumitomo Forestry. There are also more than 800 life sciences companies operating in the state, employing over 75,000 people in contact research, medical device manufacturing, biotech and more.